Evaluation of the plasma concentration of ponatinib in a chronic myeloid leukaemia patient with ponatinib intolerance.
J Clin Pharm Ther
; 46(1): 219-222, 2021 Feb.
Article
em En
| MEDLINE
| ID: mdl-32985698
ABSTRACT
WHAT IS KNOWN AND OBJECTIVE:
Some patients with chronic myeloid leukaemia (CML) cannot continue tyrosine kinase inhibitor (TKI) treatment due to intolerance associated with higher plasma concentration. CASESUMMARY:
A 76-year-old woman with chronic-phase CML who showed resistance/intolerance to pre-TKIs has been treated with ponatinib. A high ponatinib bioavailability was noted; therefore, we administered ponatinib 15 mg/3 d to avoid adverse events due to high exposure. Eventually, the patient achieved a major molecular response. WHAT IS NEW ANDCONCLUSION:
Monitoring of the ponatinib plasma concentration led to safe and effective CML management in a patient with higher drug bioavailability.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Piridazinas
/
Leucemia Mielogênica Crônica BCR-ABL Positiva
/
Imidazóis
/
Neutropenia
/
Antineoplásicos
Limite:
Aged
/
Female
/
Humans
Idioma:
En
Revista:
J Clin Pharm Ther
Assunto da revista:
FARMACIA
/
TERAPEUTICA
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Japão